Last reviewed 2026-05-13 · How we verify

9MW0813

9MW0813 is a monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.

9MW0813 is a monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).

At a glance

Mechanism of action

By binding to PD-L1 on tumor cells and immune cells, 9MW0813 prevents the engagement of PD-L1 with its receptors on T cells, thereby releasing the brake on T-cell activation and proliferation. This allows the immune system to mount a more robust anti-tumor response. The drug is designed to restore anti-tumor immunity in patients with PD-L1-expressing malignancies.

Approved indications

• Non-small cell lung cancer
• Other solid tumors (under investigation in Phase 3)

Common side effects

• Fatigue
• Decreased appetite
• Immune-related adverse events (pneumonitis, hepatitis, colitis)
• Infusion-related reactions

Key clinical trials

• Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema (PHASE3)
• Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• 9MW0813 CI brief — competitive landscape report
• 9MW0813 updates RSS · CI watch RSS
• Mabwell (Shanghai) Bioscience Co., Ltd. portfolio CI